Brain metastasis and treatment
Manmeet S. Ahluwalia¹, Michael A. Vogelbaum¹, Samuel T. Chao¹ and Minesh M. Mehta*²

Addresses:¹Burkhardt Brain Tumor Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA;²Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
*Corresponding author: Minesh M. Mehta (mmehta@umm.edu)
F1000Prime Reports 2014, 6:114 (doi:10.12703/P6-114)
All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/6/114

Abstract
Despite major therapeutic advances in the management of patients with systemic malignancies, management of brain metastases remains a significant challenge. These patients often require multidisciplinary care that includes surgical resection, radiation therapy, chemotherapy, and targeted therapies. Complex decisions about the sequencing of therapies to control extracranial and intracranial disease require input from neurosurgeons, radiation oncologists, and medical/neuro-oncologists. With advances in understanding of the biology of brain metastases, molecularly defined disease subsets and the advent of targeted therapy as well as immunotherapeutic agents offer promise. Future care of these patients will entail tailoring treatment based on host (performance status and age) and tumor (molecular cytogenetic characteristics, number of metastases, and extracranial disease status) factors. Considerable work involving preclinical models and better clinical trial designs that focus not only on effective control of tumor but also on quality of life and neurocognition needs to be done to improve the outcome of these patients.

Introduction
Brain metastases are the most common and devastating neurologic complications of systemic cancer and occur in 10% to 30% of adults with cancer [1]. The incidence of brain metastases is increasing because of better detection from improved imaging techniques, more frequent utilization of brain magnetic resonance imaging (MRI) for staging asymptomatic patients, and more effective systemic treatment regimens that can prolong life, permitting the cancer to disseminate to the brain, a sanctuary site [2]. Common systemic malignancies that result in brain metastases include lung, breast, unknown primary, melanoma, and renal cell carcinoma [2]. Most brain metastases are supratentorial in location (80%), and the cerebellum and brain stem account for 15% and 5%, respectively [3]. In the past, survival of patients with brain metastases was dismal, there was considerable nihilism in management recommendations, and patients were treated with palliative intent only, typically consisting of whole-brain radiotherapy (WBRT) alone.

More definitive treatments, including surgery and stereotactic radiosurgery (SRS), were used only sporadically or for palliative effect, particularly for histologies that are resistant to fractionated radiotherapy [4–7]. This nihilistic approach to the management of patients with brain metastases changed following the publication of multiple prospective randomized studies, which demonstrated a survival benefit with surgery or SRS as adjucts to WBRT [8,9]. New biological insights and the development of novel cytotoxic agents and targeted therapies that have better blood-brain barrier (BBB) penetration have elevated the interest in systemic therapies for this clinical challenge. In particular, in human epidermal growth factor receptor 2-positive (HER2⁺) breast cancer, epidermal growth factor receptor (EGFR)-mutated as well as anaplastic lymphoma kinase (ALK)-translocated non-small cell lung cancer (NSCLC), and some melanomas, and integration of targeted agents and immune check-point inhibitors in the management of brain metastases are gaining considerable traction.
Graded prognostic index

The recursive partitioning analysis (RPA), derived from older Radiation Therapy Oncology Group (RTOG) clinical trials, divided patients into three prognostic categories based on Karnofsky performance status (KPS), age, and primary tumor control [10]. The patients in group I had better outcomes than patients in group III (overall survival (OS) 7.1 versus 2.3 months). A more recent diagnosis-specific graded prognostic assessment (DS-GPA) is based on an analysis of approximately 4000 patients with newly diagnosed brain metastases treated between 1985 and 2007 [11]. Multivariate analysis of patients in this database led to the establishment of separate criteria for patients with lung cancer, breast cancer, melanoma, renal cell carcinoma, and gastrointestinal cancer. Further research to elucidate the subtypes of each cancer (for example, NSCLC and breast cancer) has been reported [12,13]. In breast cancer, the tumor subtype based on HER2/estrogen receptor/progesterone receptor status is prognostic for OS [12], and the DS-GPA model is being used to stratify patients in an ongoing RTOG study (NCT01622868). In a cohort of patients with NSCLC, EGFR mutation and EML4-ALK translocation were shown to represent radiosensitive genotypes, whereas those harboring KRAS mutations had poor local control [13].

Resection of brain metastases

Multiple potential benefits are associated with the use of surgery for brain metastases. Surgical removal of a brain metastasis can lead to immediate elimination of life-threatening or symptom-generating mass effect and elimination of the source of perifocal edema. Surgery has the added benefit of reducing the requirement for and duration of steroid therapy [14]. Surgery is also of value when the diagnosis is unknown or unclear. This is particularly the case when a patient has no known primary tumor or has a primary cancer histology that is unlikely to metastasize to the brain (for example, prostate carcinoma) or a brain lesion that appears several years after the initial primary tumor [15]. It should be kept in mind that, even in patients with a known primary cancer, a newly diagnosed brain mass can turn out to be a primary brain tumor or other non-metastatic disease in about 9% of cases [9].

Surgery can also provide a survival benefit, as evidenced by two prospective phase III studies. Patchell and colleagues [9] prospectively randomly assigned 48 patients with a single brain metastasis to surgical resection followed by WBRT or WBRT only. The median survival of patients in the surgical group followed by WBRT was significantly prolonged compared with that of the radiotherapy-only group (40 versus 15 weeks, \( P < 0.01 \)), as was length of functional independence (38 versus 8 weeks, \( P < 0.005 \)) [9]. Similarly, Vecht and colleagues [16] randomly assigned 63 patients to surgery and WBRT versus WBRT only and observed a significant prolongation in survival (10 versus 6 months, \( P = 0.04 \)) and a trend toward improved maintenance of functional independence [16]. One negative study randomly assigned 84 patients to surgery and WBRT versus WBRT and found no significant difference in survival (5.6 versus 6.3 months, \( P = 0.24 \)) or maintenance of functional independence [17]. It should be noted, however, that 73% of patients in this study had poorly controlled extracranial disease, there was unequal distribution of primary pathologies between the groups, and non-uniform calculation of survival times.

The evidence supporting the use of resection for the treatment of multiple brain metastases is less robust, and no prospective randomized studies have addressed this question. Older uncontrolled retrospective studies suggested that patients with multiple brain metastases did not benefit from surgery, compared with the historical results with WBRT alone [18,19]. A more recent retrospective study found that patients who underwent removal of all metastases (mostly patients with two lesions) had a significantly longer survival than those in whom at least one lesion was not resected (14 versus 6 months) [4].

Surgical technique has also been the subject of retrospective, but not prospective, evaluation. Some surgeons have advocated the use of “en bloc” techniques, rather than piecemeal resection, in order to reduce the risk of tumor recurrence and leptomeningeal tumor spread [19–21]. This may be a particularly important concern for posterior fossa tumors, in which the risk of leptomeningeal spread appears to be higher than for supratentorial tumors [20,21]. Not all tumors may be resectable in an en bloc manner, however, because of their size, location, and physical characteristics (for example, tumors with a poorly formed capsule).

Whole-brain radiation therapy

One of the first descriptions of WBRT is from Chao and colleagues [22], who showed that 24 out of 38 patients achieved palliation but that half of these patients recurred by 3.5 months. Borget and colleagues [23] reviewed dosing by using the results of two RTOG trials, showing equivalency between various dose fractionation schemes. Currently, 30 Gy in 10 fractions or 37.5 Gy in 15 fractions is considered a “standard” dose for WBRT.

After the 1990 study by Patchell and colleagues, the next logical question was whether WBRT is necessary after resection. A randomized study showed that the addition of WBRT, after complete tumor resection, decreased intracranial failure from 70% to 18% (\( P < 0.001 \)) and
decreased local recurrence from 46% to 10% (P < 0.001) [24]. Although there was improved survival with the use of WBRT, this was not statistically significant, and this study was not powered for assessing a survival benefit. WBRT is therefore typically recommended as adjuvant therapy following surgery.

Typical side effects from WBRT include hair loss, fatigue, headache, skin erythema, and serous otitis media. Somnolence syndrome is rare but may be seen. Long-term side effects include memory loss and leukoencephalopathy. Although neurocognitive dysfunction is typically mild to moderate in most people, this remains the most distressing side effect of WBRT. The RTOG conducted two studies to try to mitigate the neurocognitive effect of WBRT. RTOG 0614 randomly assigned patients to receive memantine, an N-methyl-D-aspartate (NMDA) receptor-agonist, versus placebo [25]. The memantine arm had significantly longer time to cognitive decline (P = 0.02). Median declines on Hopkins Verbal Learning Test-Revised (HVLT-R) were 0 in the memantine arm and -2 in the placebo arm at 24 weeks (P = 0.059). Also, fewer patients had a decline in Controlled Oral Word Association (COWA) at 16 weeks (P = 0.004) or Trail Making Test Part A at 24 weeks (P = 0.014). Memantine is started at a low dose and increased to 10 mg twice daily over the course of a few weeks. Patients continue on memantine for 6 months. In general, since patients have to take the drug for 6 months and the benefits of this treatment are best seen afterwards, memantine is best given when life expectancy is 6 months or more.

Hippocampal neural stem cell injury from irradiation during WBRT may play a role in memory decline. Intensity-modulated radiotherapy can be used to conformally avoid the hippocampal neural stem cell compartment during WBRT (hippocampal avoidance [HA]-WBRT). RTOG 0933 was a single-arm phase II study of HA-WBRT for brain metastases with pre-specified comparison with a historical control of patients treated with WBRT without hippocampal avoidance. The primary endpoint was the Hopkins Verbal Learning Test-Revised Delayed Recall (HVLT-R DR) at 4 months. The historical control demonstrated a 30% mean relative loss in HVLT-R DR from baseline to 4 months. To detect a mean relative loss of not more than 15% in HVLT-R DR following HA-WBRT, 51 analyzable patients were required to ensure 80% statistical power with an alpha of 0.05. Quality of life (QOL) assessments included the Functional Assessment of Cancer Therapy and Barthel Activities of Daily Living. Mean relative decline in HVLT-R DR from baseline to 4 months was 7.0% (95% confidence interval [CI]−4.7% to +18.7%), which was significantly lower in comparison with the historical control (P = 0.0003). No decline in QOL scores up to 6 months was observed [26].

### Stereotactic radiosurgery

SRS involves the delivery of a high dose of radiation focally to the tumor, usually in a single fraction. SRS may be based on a linear particle accelerator or performed with fixed radiation sources, such as Gamma Knife™ (Elekta, Stockholm, Sweden). SRS is largely non-invasive, does not require general anesthesia, and is performed on an outpatient basis. It has now become the most widely used focal treatment modality for patients with brain metastasis. RTOG 9005 prospectively identified appropriate and safe doses of SRS, based on lesion size. This study showed that prescription doses of 15, 18, and 24 Gy to the tumor margin were the maximal safe doses for lesions with diameters of 31 to 40, 21 to 30, and 20 mm or less, respectively [27]. Controversies remain about selecting the exact SRS dose for various disease entities and lesion sizes [28,29].

The efficacy of SRS for brain metastases was first reported in multiple retrospective studies. A large retrospective multi-institutional analysis of 502 patients stratified by RPA class (I, II, and III) by Sanghavi and colleagues [30] showed that patients receiving WBRT and SRS compared with WBRT alone had significantly increased median survival times of 16.1 versus 7.1 months, 10.3 versus 4.3 months, and 8.7 versus 2.1 months, respectively (P < 0.05). A randomized controlled phase III trial (RTOG 9508) of WBRT + SRS versus WBRT alone enrolled 333 patients with one to three brain metastases and a KPS of 70 or greater [31]. Patients with a single lesion had a decreased rate of local recurrence at 1 year (18% versus 29%, P = 0.01) and superior median survival (6.5 versus 4.9 months, P = 0.039) when they received both WBRT and SRS compared with only WBRT. For patients with multiple (two or three) metastases, survival was not significantly improved but local control was. SRS and WBRT also resulted in better outcomes compared with WBRT alone in terms of maintenance or improvement of KPS and steroid use. A smaller prospective study by Kondziolka and colleagues [32] compared WBRT alone versus WBRT plus SRS. This randomized trial was terminated early and enrolled only 27 patients with two to four metastases. Local control rates were 0% and 92% for the WBRT only group and the WBRT plus SRS group, respectively. Though not statistically significant, the WBRT plus SRS group had an increased median survival time of 11.0 compared with 7.5 months for WBRT only.

The role of SRS alone, without WBRT, was investigated in subsequent trials. A large retrospective multi-institutional analysis of 569 patients (268 receiving SRS alone and 301 receiving SRS plus WBRT) showed similar median survivals when stratified by RPA class [33]. Pirzkall and colleagues [34] found that there was no
significant difference in median survival between SRS alone and SRS plus WBRT in a retrospective analysis of 236 patients, with the exception of one subset of patients. A single-arm, prospective phase II Eastern Cooperative Group trial for patients with “radioresistant” metastases (renal cell, melanoma, and sarcoma) demonstrated a 6-month local and overall intracranial failure rate of 32%, which was considered to be better than the reported tumor control rates for WBRT for these histologies [35]. A randomized trial evaluating the use of SRS with or without WBRT showed no survival difference (8.0 months for SRS versus 7.5 months for SRS plus WBRT; \( P = 0.42 \)); however, the trial was not powered to detect a significant difference in OS [8].

A prospective randomized Japanese study demonstrated that local control rates were improved with the addition of WBRT to SRS, and 1-year failure rates were 23.6% for SRS and 53.2% for SRS only \( (P < 0.001) \). In addition, mini-mental status exam (MMSE) was stable for approximately 2 years after SRS and WBRT compared with SRS alone [36]. The improved local control coupled with stabilization of MMSE suggests the beneficial effect of WBRT on decreasing brain tumor recurrence. Chang and colleagues [37] performed a phase III study for patients with one to three lesions comparing SRS plus WBRT versus SRS alone with the primary endpoint of neurocognitive function measured by the HVLT-R. After accrual of 58 patients, the trial was stopped early based on a high probability that the patients receiving SRS and WBRT would show a statistically significant decline in learning and memory function (total recall) at 4 months. In that study (as in the Japanese study), there were more central nervous system (CNS) recurrences in the group receiving SRS alone; 73% of patients in the SRS and WBRT group were free from CNS recurrence at 1 year, compared with 27% of patients who received SRS alone \( (P = 0.0003) \).

The North Central Cancer Treatment Group (NCCTG) has recently completed accrual to a phase III trial (N0574) comparing SRS versus SRS followed by WBRT delivered within 14 days for patients with one to three brain metastases. Results are pending. According to emerging data presented by Sahgal and colleagues [38], for patients 50 years or younger with one to four brain metastases, there is an OS advantage to SRS alone based on a meta-analysis of three phase III studies (10 versus 8.2 months).

SRS has also been used as salvage therapy in progressive disease following WBRT. A 111-patient retrospective study from the Cleveland Clinic demonstrated a local control rate of 73% with SRS, with a median follow-up of 15.4 months [39]. Although SRS is typically offered for patients with four or fewer brain metastases, SRS is increasingly being used for patients with five or more brain metastases. A retrospective review from the Cleveland Clinic found that the median OS after SRS for five or more brain metastases was 7.5 months [40]. KPS of 80 or more was a significant predictor for survival. Interestingly, the number of brain metastases was not a significant predictor of survival, but this may have been due to the relatively small size of the study. Higher intracranial burden (higher volume of brain metastases within the brain) predicted poorer outcomes [41]. The Japanese Leksell Gamma Knife Society conducted a study for one to 10 brain metastases and showed no difference in OS whether patients had two to four versus five or more brain metastases when treated with SRS alone [42]. This suggests that SRS alone may be a reasonable approach in selected patients with up to 10 brain metastases.

Another active area of investigation is the use of SRS to prevent local recurrence after resection in lieu of WBRT. Rather than targeting an enhancing tumor, resection bed SRS can be made more complex because of uncertainties regarding the interpretation of a postoperative MRI. Soltys and colleagues [43] reported 1-year local control rates of 94% when a 2 mm margin was added around the defined tumor bed and 78% when no margin was added. Median OS was 17 months, and 72% of patients were able to avoid WBRT. One concern regarding surgical bed SRS is the possibility of leptomeningeal spread secondary to the resection, especially for patients with breast cancer and those with posterior fossa disease [44]. The NCCTG, in collaboration with RTOG, is conducting a study randomly assigning patients to WBRT versus resection bed SRS.

One novel approach to potentially minimizing leptomeningeal spread is to perform SRS prior to resection, which would “sterilize” the tumor cells prior to the resection. Neoadjuvant SRS was reported by Asher and colleagues [45]. This study involved 47 patients, 24 of whom were treated prospectively. These patients underwent SRS to a median dose of 14 Gy (range of 11.8 to 18). Surgery was performed a median of 1 day after SRS. Local control was good at 85.6% at 1 year, and only 14.8% of the patients eventually required WBRT. There were no leptomeningeal failures. Given these results, the Cleveland Clinic is conducting a dose escalation study with neoadjuvant SRS for lesions that are 2 to 5 cm in diameter.

Whether SRS can replace surgery remains unanswered in terms of level 1 evidence. An international randomized phase III trial compared surgery or radiosurgery with or without adjuvant WBRT and noted that the addition of WBRT to either surgery or radiosurgery did not alter
survival but did improve CNS control and reduced the risk of death due to intracranial progression [46]. This study, however, did not specifically compare surgery with radiosurgery. More than one randomized effort to answer this question has failed because of poor accrual and preconceived bias. Therefore, only retrospective studies are available to address this issue. Bindal and colleagues [7] reported on a retrospectively matched series of 75 patients treated by surgery and SRS. The median survival rates were 7.5 months with SRS and 16.4 months in the surgical group. There is concern, however, that the dosing regimen used in the radiosurgery group resulted in the use of lower prescriptions to the tumor margin than would be considered standard according to the widely accepted RTOG dosing schema [27,31]. Auchter and colleagues [47] retrospectively analyzed a multi-institutional dataset of SRS in 122 highly selected patients with a resectable single metastable brain tumor. The median survival was 56 weeks, comparable to the results of most surgical series. A retrospective study from Muacevic and colleagues [48] compared surgery and radiotherapy with radiosurgery for patients with a single tumor 3.5 cm or less in diameter. The 1-year survival rates (53% versus 43%, P = 0.19), 1-year local control rates (75% versus 83%, P = 0.49), and 1-year neurologic death rates (37% versus 39%, P = 0.8) for the surgical group and SRS group, respectively, were not statistically different. Schoggl and colleagues [49] treated 133 patients with either radiosurgery (SRS, n = 67) or surgery (n = 66), along with WBRT, and performed a retrospective case-control analysis of their results. These investigators found no difference in median survival (SRS versus surgery, 12 versus 9 months, P = 0.19) but did find a superior local control rate with SRS (P < 0.05), likely attributable to the improved outcome of patients with histology resistant to WBRT. O’Neill and colleagues [50] retrospectively compared surgery and SRS for treatment of solitary brain metastasis and found no significant difference in patient survival. The difference in local tumor control rate, however, was significantly different (100% following SRS and 58% after surgery).

Systemic therapy
The role of systemic therapy, chemotherapy, or targeted therapy or immunotherapy in the management of patients with brain metastases is not well defined. There is no level 1 evidence favoring the use of systemic therapy compared with local therapies in brain metastases. At present, no standard cytotoxic chemotherapy is routinely used for the treatment of brain metastases. In patients with brain metastases that have failed local therapy with surgery or radiation, the same chemotherapeutic agents employed for the treatment of extracranial disease are often used. Alternatively, drugs with good CNS penetration, such as temozolomide, topotecan, and irinotecan, may be employed, even in patients in whom the chemotherapy might have, at most, minor efficacy against the primary tumor. Improved understanding of tumor biology has led to the identification of specific molecular drivers of cancer development and progression. Alterations involving the EGFR gene and EML4-ALK chromosomal translocation in lung cancer, HER2 protein overexpression in breast cancer, and BRAF mutation in melanoma are examples of distinct subsets of cancer amenable to unique treatment approaches. A number of prospective studies in the last 3 to 5 years have particularly focused on targeted therapy or immunotherapy.

Inhibitors targeting EGFR in non-small cell lung cancer
The combination of targeted therapy or chemotherapy with WBRT has the premise of these agents serving as a potential radiation sensitizer to increase the efficacy of the radiation. However, the RTOG 0320 trial did not show any additional benefit of temozolomide or erlotinib when added to WBRT and SRS in patients with NSCLC with one to three brain metastases [51]. In fact, the patients in the control arm of SRS and WBRT had the best outcomes; progression-free survival (PFS) and OS were 8.1 and 13.4 months for WBRT and SRS compared with 4.6 and 6.3 months for WBRT, SRS, and temozolomide and 4.8 and 6.1 for WBRT, SRS, and erlotinib [51]. However, one of the limitations of the study was that patients were not stratified according to EGFR mutational status. In a phase II study of 40 NSCLC patients with brain metastases, the combination of WBRT and erlotinib was safe (no reported increase in neurotoxicity) and the median survival time was 11.8 months [52]. In the 17 patients with known EGFR status, the benefit of erlotinib was more pronounced in the mutant EGFR patients (OS of 19.1 months) as compared with the wild-type EGFR patients (OS of 9.3 months) [52]. In a large cohort of 110 patients with EGFR mutant lung cancer with newly diagnosed brain metastases, patients treated with WBRT (32 patients) had longer median time to intracranial progression compared with 63 patients who received erlotinib therapy upfront (24 versus 16 months) [53]. Patients treated with erlotinib or SRS experienced intracranial failure as a component of first failure more commonly, whereas WBRT patients experienced failure outside the brain more often. The OS was similar between the WBRT and erlotinib groups, and patients treated with SRS initially had a longer OS compared with those who received erlotinib.

In a prospective phase II study of gefitinib in 41 NSCLC patients unselected for EGFR mutation, an objective response rate of 10% in the brain was seen [54]. Higher response rates were reported in studies of EGFR inhibitors...
in enriched with patients with known EGFR mutations \[55,56\]. In a phase II study of 28 patients with EGFR mutant NSCLC with brain metastases, a partial response rate of 83% and a disease control rate of 93% were seen with treatment with erlotinib or gefitinib \[55\].

**Inhibitors targeting HER2 in breast cancer**

Several prospective clinical trials have evaluated the role of lapatinib-based therapy in HER2\(^+\) breast cancer patients with active brain metastases \[57–60\]. In a large phase II study of lapatinib in 242 patients with HER2\(^+\) breast cancer and progressive brain metastases after WBRT or SRS (or both), a CNS response rate of 6% was seen \[58\]. Fifty patients who progressed were treated with a combination of lapatinib and capecitabine, and 20% achieved a CNS objective response. In the Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases from HER2-positive Metastatic Breast Cancer (LANDSCAPE) study, a single-arm, phase II study, 29 of the 45 patients with newly diagnosed, previously untreated brain metastases achieved an objective CNS response \(66\)\%, albeit all were partial responses \[60\]. A randomized phase II study of WBRT with or without lapatinib in patients with HER2\(^+\) breast cancer with brain metastases is ongoing \[NCT01622868\].

**Inhibitors targeting BRAF in melanoma**

Activating BRAF mutations that result in constitutive activation of the mitogen-activated protein kinase pathway affect approximately half of patients with melanoma, and more than 95% of these are the V600E mutation (substitution of valine by glutamic acid at the 600th amino acid position) \[61\]. In an open-label phase II study, BRAF-mutant melanoma metastatic to the brain (BREAK-MB), 172 patients with V600E or V600K mutation-positive melanoma metastatic to the brain were treated with dabrafenib \[62\]. Patients in cohort A had not received any prior local therapy, and cohort B had disease progression in the brain following local therapy (surgery, WBRT, and SRS). Twenty-nine \(39\%\) of 74 patients with V600E BRAF-mutant melanoma in cohort A and 20 of 65 patients in cohort B achieved an overall intracranial response. This study provided initial evidence that dabrafenib has activity in patients with V600E BRAF-mutant melanoma brain metastases irrespective of prior local therapy.

In a prospective study, 24 patients with V600E BRAF mutation-positive melanoma brain metastases were treated with vemurafenib. Of 19 patients with measurable intracranial disease, 7 \(37\\%\) achieved at least 30% intracranial tumor regression, and 3 \(16\%\) achieved a confirmed partial response, whereas 13 \(62\\%\) out of 21 patients had extracranial responses \[63\]. In a retrospective study of 283 patients with V600 BRAF mutation-positive melanoma brain metastases, 136 \(48.1\%\) out of 283 were reported to achieve overall intracranial response (complete response/partial response). OS at 6 months was an impressive 86%. A phase II study of vemurafenib in 146 patients with V600 BRAF mutation-positive melanoma brain metastases \(NCT01378975\), with or without prior treatment for their brain metastases, has completed accrual.

**Immune-modulating approaches**

The development of immune-modulating agents, specifically immune checkpoint inhibitors, offers an exciting opportunity for treating patients with brain metastases. Previously, immunotherapy was thought to be ineffective in patients with brain tumors and brain metastases because it was felt that these agents would not cross an intact BBB and that, even if they did, the ability to mount a robust immune response in the brain would be somewhat limited. However, recent research has demonstrated that activated T cells can be effective in brain metastases and other intracranial tumors \[64\]. In a phase II study, 72 melanoma patients with brain metastases were treated with ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) \[65\]. Cohort A consisted of 51 patients who were neurologically asymptomatic and not on corticosteroids, and cohort B included 21 patients who were neurologically symptomatic and on steroids. Twelve \(24\%\) of 51 patients in cohort A and two \(10\%\) of 21 patients in cohort B achieved CNS disease control (partial response or stable disease). Median OS rates were 7.0 months in cohort A and 3.7 months in cohort B. This study demonstrated that ipilimumab could have some activity in recurrent brain metastases, and further evaluation, especially in a combinatorial manner, is proceeding.

**Primary endpoints in trials of brain metastases**

The choice of endpoints in brain metastases trials is challenging because of the need to account for not only intracranial metastases but also extracranial disease. OS is usually the primary endpoint in phase III trials of brain metastases. However, up to 60% of patients with brain metastases die from extracranial disease progression independently of intracranial disease control \[66\]. Hence the use of OS as the primary endpoint in brain metastases trials may not be reflective of the activity of the agent or the modality in the brain as majority of patients die of extracranial disease \[67\]. The use of PFS as the primary endpoint in brain metastases trials in studies of SRS with or without WBRT is limited by its ability to take into account the concerns about neurocognitive decline associated with WBRT. It can be difficult to accurately
distinguish progression from radiation-related changes, particularly after SRS by routine MRI. In addition, there are challenges related to which criteria to adopt—Response Evaluation Criteria in Solid Tumors (RECIST), World Health Organization (WHO), Macdonald, and Response Assessment in Neuro-Oncology (RANO)—to define response and progression. To circumvent these challenges and to take advantage of the fact that intracranial recurrence can be managed effectively with close surveillance, some of the recent trials have employed neurocognitive outcomes as the primary endpoint and have focused on functional status and QOL as secondary endpoints [37]. The RANO working group is making an active ongoing effort to define the appropriate endpoints to adopt in brain metastases trials (personal communication, Patrick Wen).

Other approaches and future trial directions
One approach is to consider preventive strategy in patients at high risk for developing brain metastases. A number of drugs can potentially help prevent the overt development of brain metastases (for example, temozolomide, pazopanib, and vorinostat) [68]. Mouse models developed in the laboratory of Steeg and colleagues [68] have suggested that temozolomide could putatively decrease the emergence of brain metastases in breast cancer, and a clinical trial to test this concept is planned by the Southwest Oncology Group (SWOG) (Christina Tsien and colleagues, personal communication). A trial of temozolomide after definitive treatment in locoregionally advanced NSCLC failed to demonstrate any reduction in the development of brain metastases (Robins HI, personal communication). A phase III trial compared lapatanib plus capecitabine versus trastuzumab plus capecitabine with the aim that the former combination of lapatinib and capecitabine would prevent the development of CNS metastases [69]. The study failed to meet its primary endpoint, possibly because it required brain imaging at baseline that resulted in a 20% rate of screen failure, which likely resulted in a paucity of events, making the study underpowered to address the prevention question. The development of targeted therapy (small-molecule inhibitors) with better BBB penetration and improved molecular and clinical predictors to enrich for patients with a high risk of brain metastases will aid such future studies.

Another approach that has gained traction in the last few years is of secondary prevention, in which patients with limited brain metastases (usually one to four brain metastases) are treated with SRS and then receive a targeted agent (with good BBB penetration) to control both the intracranial micro-metastases and the systemic disease. The aim is to avoid WBRT in patients who have good performance status and prognosis until patients relapse to mitigate or delay the neurocognitive side effects of WBRT. An ongoing phase II study of the combination of dabrafenib with SRS in BRAF V600E melanoma brain metastases uses this strategy (NCT01721603). An institutional trial using lapatanib/capecitabine or trastuzumab-emsitansine (TDM-1) in HER 2+ breast cancer patients with one to 10 brain metastases treated with radiosurgery is in development (Minesh Mehta and colleagues, personal communication). Furthermore, a recently approved device, NovoTTF, which delivers low-voltage alternating electrical current to the brain and which has been approved for use in recurrent glioblastoma, is being considered under a company-sponsored trial in patients with NSCLC and one to 10 brain metastases treated with SRS (Vinai Gondi and colleagues, personal communication).

Significant interest remains in minimizing the impact of WBRT. Based on the encouraging results with the use of memantine as well as hippocampal sparing, further trials incorporating both strategies are being pursued. Trials avoiding WBRT are also under way; an intergroup trial of SRS with or without WBRT in patients with one to four brain metastases has completed accrual, and a similar industry-supported trial in patients with one to 10 brain metastases is under way.

Summary and Conclusions
The treatment of patients with brain metastases requires a multidisciplinary team approach in which treatment recommendations (surgery, WBRT, SRS, and systemic therapy) are based on host (performance status and age) and tumor (type and subtype of tumor, number of metastases, and extracranial disease status) factors. An individualized plan to improve the outcome of patients with this life-limiting complication is optimal. Molecularly defined disease subsets and targeted therapies as well as immunotherapeutic agents will aid in improved outcomes in patients with brain metastases. WBRT retains an important place in the management of this disease, but its application and role are being rapidly redefined.

Abbreviations
Disclosures
Manmeet Ahluwalia has received honorarium from Elekta. Michael Vogelbaum declares that he has no disclosures. Samuel Chao has served on a speakers bureau for Varian. Minesh Mehta has served as a consultant for Abbott, Bristol-Myers Squibb, Elekta, Genentech, Merck, Novocure, and Phillips and is on the board of directors of Pharmacyclics and has stock options.

References


59. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Cheung YK, Eder JP,缺少了具体信息。

58. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Cheung YK, Eder JP,缺少了具体信息。

57. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Cheung YK, Eder JP,缺少了具体信息。